Comparative Pharmacology
Head-to-head clinical analysis: NUZYRA versus PANMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUZYRA versus PANMYCIN.
NUZYRA vs PANMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Omadacycline is a aminomethylcycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
200 mg intravenously once on day 1, then 100 mg IV once daily; or 200 mg orally once on day 1, then 100 mg orally once daily.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
None Documented
None Documented
Terminal elimination half-life is approximately 17-21 hours; supports once-daily dosing.
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Fecal (approximately 76%) as unchanged drug; renal (approximately 14%) as unchanged drug; biliary excretion is minimal.
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic